Gary Monk

Digital

In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.